Rare disease focus Target opportunities in rare and debilitating digestive diseases leveraging 9 Meters Biopharma's clinical-stage programs and unique GI biology expertise to engage specialty investors, patient advocacy groups, and CRO partners for collaboration or licensing discussions.

GIP antagonist potential Explore partnerships around NM-136, the anti-GIP hu-mAb for obesity disorders, including strategic collaborations with pharma companies seeking obesity/metabolic disease assets, given ongoing IND-enabling work and FDA pre-IND engagement.

Clinical and regulatory momentum Capitalize on recent regulatory milestones such as Pre-IND meetings and ongoing IND-enabling studies to approach potential sponsors, contract research organizations, and financial partners interested in late preclinical to early clinical stage programs.

Strategic financing signals Leverage the company’s $130M funding base and recent debt financing to discuss co-development, milestone-based funding, or convertible debt opportunities with interested investors and strategic partners seeking early-stage biotech exposure.

Collaborative potential Position for alliances with international research centers and large pharma focused on gastroenterology and cancer biology, inspired by past collaboration with Gustave Roussy, to explore joint research, access to patient cohorts, and regional regulatory expertise.